Orsiro™ Drug Eluting Stent in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

1,007

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

January 31, 2022

Conditions
Angioplasty, Transluminal, Percutaneous CoronaryCoronary Artery Disease
Interventions
DEVICE

Orsiro™ Drug Eluting Stent group

Trial Locations (18)

Unknown

Hallym University Sacred Heart Hospital, Anyang

Soon Chun Hyang University Hospital Bucheon, Bucheon-si

Dankook University Hospital, Cheonan

Soon Chun Hyang University Hospital Cheonan, Cheonan

Gangwon National Univ. Hospital, Chuncheon

Daegu Catholic University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

The Catholic University of Korea, Daejeon ST. Mary's Hospital, Daejeon

Gangneung Asan Hospital, Gangneung

Chonnam National University Hospital, Gwangju

Gachon University Gil Hospital, Incheon

Inje University Pusan Paik Hospital, Pusan

Pusan National University Yangsan Hospital, Pusan

Asan Medical Center, Seoul

Gangnam Severance Hospital, Seoul

Kangdong Sacred Heart Hospital, Seoul

Korea University Guro Hospital, Seoul

Ulsan University Hospital, Ulsan

All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

collaborator

Biotronik Korea Co., Ltd

INDUSTRY

lead

Seung-Jung Park

OTHER

NCT02039739 - Orsiro™ Drug Eluting Stent in Routine Clinical Practice | Biotech Hunter | Biotech Hunter